Illumina, Inc. (NASDAQ:ILMN) Given Average Recommendation of “Hold” by Analysts

Shares of Illumina, Inc. (NASDAQ:ILMN) have been assigned an average recommendation of “Hold” from the twenty-one ratings firms that are currently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, eleven have given a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month target price among analysts that have covered the stock in the last year is $157.62.

Several brokerages recently commented on ILMN. Evercore ISI reduced their price target on Illumina from $195.00 to $175.00 and set an “outperform” rating for the company in a research report on Tuesday, June 11th. Scotiabank dropped their price objective on shares of Illumina from $185.00 to $176.00 and set a “sector outperform” rating for the company in a research note on Monday, May 6th. Stephens restated an “overweight” rating and issued a $170.00 target price on shares of Illumina in a research report on Tuesday, May 7th. OTR Global restated a “mixed” rating on shares of Illumina in a research report on Wednesday, March 20th. Finally, StockNews.com initiated coverage on shares of Illumina in a research report on Sunday. They issued a “buy” rating for the company.

Institutional Investors Weigh In On Illumina

A number of institutional investors have recently added to or reduced their stakes in the business. Transcend Capital Advisors LLC grew its holdings in Illumina by 56.0% during the 2nd quarter. Transcend Capital Advisors LLC now owns 5,227 shares of the life sciences company’s stock worth $546,000 after acquiring an additional 1,877 shares during the last quarter. DekaBank Deutsche Girozentrale boosted its stake in shares of Illumina by 0.8% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 102,049 shares of the life sciences company’s stock valued at $13,969,000 after purchasing an additional 805 shares during the last quarter. Cetera Advisors LLC bought a new stake in shares of Illumina in the 1st quarter valued at $610,000. Cetera Investment Advisers boosted its stake in shares of Illumina by 361.1% in the 1st quarter. Cetera Investment Advisers now owns 14,617 shares of the life sciences company’s stock valued at $2,007,000 after purchasing an additional 11,447 shares during the last quarter. Finally, PGGM Investments boosted its stake in shares of Illumina by 7.4% in the 1st quarter. PGGM Investments now owns 227,578 shares of the life sciences company’s stock valued at $31,251,000 after purchasing an additional 15,744 shares during the last quarter. 89.42% of the stock is owned by institutional investors.

Illumina Stock Down 0.2 %

ILMN stock opened at $105.28 on Thursday. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.75 and a quick ratio of 1.36. The stock has a market capitalization of $16.77 billion, a P/E ratio of -12.92 and a beta of 1.15. The business has a 50-day moving average of $110.95 and a 200-day moving average of $126.99. Illumina has a fifty-two week low of $89.00 and a fifty-two week high of $195.64.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, May 2nd. The life sciences company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.04 by $0.05. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The firm had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.05 billion. During the same period in the prior year, the firm posted $0.08 earnings per share. The business’s quarterly revenue was down 1.0% compared to the same quarter last year. On average, sell-side analysts anticipate that Illumina will post 0.98 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.